ATE328604T1 - Verwendung von wachstumshormon in niederen dosen - Google Patents

Verwendung von wachstumshormon in niederen dosen

Info

Publication number
ATE328604T1
ATE328604T1 AT01914289T AT01914289T ATE328604T1 AT E328604 T1 ATE328604 T1 AT E328604T1 AT 01914289 T AT01914289 T AT 01914289T AT 01914289 T AT01914289 T AT 01914289T AT E328604 T1 ATE328604 T1 AT E328604T1
Authority
AT
Austria
Prior art keywords
growth hormone
less
day
low dose
therapy
Prior art date
Application number
AT01914289T
Other languages
English (en)
Inventor
David B Dunger
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE328604T1 publication Critical patent/ATE328604T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01914289T 2000-03-13 2001-03-13 Verwendung von wachstumshormon in niederen dosen ATE328604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000837A SE0000837D0 (sv) 2000-03-13 2000-03-13 New use

Publications (1)

Publication Number Publication Date
ATE328604T1 true ATE328604T1 (de) 2006-06-15

Family

ID=20278800

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914289T ATE328604T1 (de) 2000-03-13 2001-03-13 Verwendung von wachstumshormon in niederen dosen

Country Status (13)

Country Link
US (2) US6696414B2 (de)
EP (1) EP1265629B1 (de)
JP (1) JP2003526675A (de)
AT (1) ATE328604T1 (de)
AU (1) AU2001239635A1 (de)
CA (1) CA2402948A1 (de)
DE (1) DE60120371T2 (de)
DK (1) DK1265629T3 (de)
ES (1) ES2263601T3 (de)
NZ (1) NZ533844A (de)
PT (1) PT1265629E (de)
SE (1) SE0000837D0 (de)
WO (1) WO2001068127A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165127A1 (en) * 1996-12-24 2002-11-07 Supergen, Inc. Methods for treating insulin resistance and identifying patients at risk for the disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US5079345A (en) * 1988-08-19 1992-01-07 Eli Lilly And Company Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
JPH04503154A (ja) 1988-11-07 1992-06-11 ルニベルシー・ド・ルタ・ア・リージュ 変型ヒト成長ホルモン
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
ATE143267T1 (de) 1992-10-29 1996-10-15 Genentech Inc Methode zur behandlung oder verhütung von fettleibigkeit
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
EP0766966A3 (de) 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
WO1999001151A1 (en) * 1997-07-04 1999-01-14 Pharmacia & Upjohn Ab Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity

Also Published As

Publication number Publication date
AU2001239635A1 (en) 2001-09-24
US20040147446A1 (en) 2004-07-29
DK1265629T3 (da) 2006-08-28
ES2263601T3 (es) 2006-12-16
CA2402948A1 (en) 2001-09-20
EP1265629B1 (de) 2006-06-07
US20010051601A1 (en) 2001-12-13
WO2001068127A1 (en) 2001-09-20
US7229965B2 (en) 2007-06-12
DE60120371T2 (de) 2007-05-16
EP1265629A1 (de) 2002-12-18
PT1265629E (pt) 2006-09-29
DE60120371D1 (de) 2006-07-20
US6696414B2 (en) 2004-02-24
JP2003526675A (ja) 2003-09-09
SE0000837D0 (sv) 2000-03-13
NZ533844A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
DE60039629D1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
IL165531A0 (en) GLP-1 and methods for treating diabetes
ATE78169T1 (de) Behandlung von diabetes durch kombinierte insulinformen.
SG146638A1 (en) Pharmaceutical delivery system
JP2006514092A5 (de)
MXPA05012810A (es) Formas de dosis oral de memantina.
SEGAL Photosensitivity, nail discoloration, and onycholysis: side effects of tetracycline therapy
PT1001802E (pt) Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
JP2002540148A5 (de)
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1265629

Country of ref document: EP

REN Ceased due to non-payment of the annual fee